MediPharm Labs 관리

관리 기준 확인 3/4

MediPharm Labs CEO는 David Pidduck, Apr2022 에 임명되었습니다 의 임기는 2.58 년입니다. 총 연간 보상은 CA$ 1.31M, 36% 로 구성됩니다. 36% 급여 및 64% 보너스(회사 주식 및 옵션 포함). 는 € 749.44K 가치에 해당하는 회사 주식의 4.08% 직접 소유합니다. 749.44K. 경영진과 이사회의 평균 재임 기간은 각각 5.1 년과 5.4 년입니다.

주요 정보

David Pidduck

최고 경영자

CA$1.3m

총 보상

CEO 급여 비율	36.0%
CEO 임기	2.6yrs
CEO 소유권	4.1%
경영진 평균 재임 기간	5.1yrs
이사회 평균 재임 기간	5.4yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

David Pidduck 의 보수는 MediPharm Labs 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-CA$12m
Jun 30 2024	n/a	n/a	-CA$13m
Mar 31 2024	n/a	n/a	-CA$14m
Dec 31 2023	CA$1m	CA$470k	-CA$13m
Sep 30 2023	n/a	n/a	-CA$16m
Jun 30 2023	n/a	n/a	-CA$20m
Mar 31 2023	n/a	n/a	-CA$26m
Dec 31 2022	CA$3m	CA$315k	-CA$30m

보상 대 시장: David 의 총 보상 ($USD 933.68K )은 German 시장( $USD 471.55K ).

보상과 수익: David 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

David Pidduck

2.6yrs

테뉴어

CA$1,305,051

보상

Mr. David A. Pidduck is Chief Executive Officer and Director at MediPharm Labs Corp. since April 20, 2022. Mr. Pidduck has been the Chief Executive Officer and President of Purdue Pharma Inc. since Septemb...

리더십 팀

이름	위치	테뉴어	보상	소유권
David Pidduck	CEO & Director	2.6yrs	CA$1.31m	4.08% € 749.4k
Keith Strachan	Co-Founder & President	5.8yrs	CA$819.48k	2.17% € 398.2k
Greg Hunter	Chief Financial Officer	3.8yrs	CA$957.75k	0.31% € 57.7k
Patrick McCutcheon	Founder	9.8yrs	CA$858.16k	데이터 없음
Brett Moon	Vice President of Sales	4.5yrs	데이터 없음	데이터 없음
Kirk Binns	Executive Vice President of Global Accounts	5.8yrs	데이터 없음	데이터 없음

5.1yrs

평균 재임 기간

경험이 풍부한 관리: MLZ 의 관리팀은 노련하고 경험 (평균 재직 기간 5.1 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
David Pidduck	CEO & Director	2.6yrs	CA$1.31m	4.08% € 749.4k
Shelley Martin	Independent Director	4.4yrs	CA$64.49k	0.020% € 3.6k
Michael Bumby	Independent Director	1.6yrs	CA$34.45k	0.050% € 9.2k
Christopher Taves	Independent Chairman of the Board	4.3yrs	CA$87.14k	0.35% € 63.6k
Miriam McDonald	Member of the Science Advisory Board	5.6yrs	CA$32.40k	데이터 없음
Leslie Brown	Member of the Science Advisory Board	5.6yrs	데이터 없음	데이터 없음
Matt Archibald	Member of the Science Advisory Board	5.6yrs	데이터 없음	데이터 없음
Markus Roggen	Member of the Science Advisory Board	5.6yrs	데이터 없음	데이터 없음
Arshad Hack	Member of the Science Advisory Board	5.6yrs	데이터 없음	데이터 없음
Jerry King	Member of the Science Advisory Board	5.6yrs	데이터 없음	데이터 없음
Carolina Landolt-Marticorena	Member of the Science Advisory Board	5.3yrs	데이터 없음	데이터 없음
Christopher Halyk	Independent Director	4.3yrs	CA$56.05k	0.043% € 7.8k

5.4yrs

평균 재임 기간

경험이 풍부한 이사회: MLZ 의 이사회는 경험(평균 재직 기간 5.4 년)으로 간주됩니다.

MediPharm Labs 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

MediPharm Labs Corp. Announces Executive Changes

MediPharm Labs Corp., Annual General Meeting, Jun 26, 2024

High number of new and inexperienced directors

Dr. Paul Tam Resigns from the Board of Directors of MediPharm Labs Corp

High number of new and inexperienced directors

MediPharm Labs Corp., Annual General Meeting, Jun 30, 2022

Recent updates

Third quarter 2024 earnings released: CA$0.007 loss per share (vs CA$0.013 loss in 3Q 2023)

MediPharm Labs Corp. to Report Q3, 2024 Results on Nov 14, 2024

MediPharm Labs Corp. Announces Executive Changes

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: CA$0.006 loss per share (vs CA$0.009 loss in 2Q 2023)

MediPharm Labs Corp. to Report Q2, 2024 Results on Aug 14, 2024

MediPharm Labs Corp., Annual General Meeting, Jun 26, 2024

First quarter 2024 earnings released: CA$0.009 loss per share (vs CA$0.01 loss in 1Q 2023)

MediPharm Labs Corp. to Report Q1, 2024 Results on May 15, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings released: CA$0.04 loss per share (vs CA$0.11 loss in FY 2022)

MediPharm Labs Corp. to Report Q4, 2023 Results on Mar 27, 2024

Third quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.03 loss in 3Q 2022)

New minor risk - Profitability

Forecast to breakeven in 2024

MediPharm Labs Corp. to Report Q3, 2023 Results on Nov 14, 2023

Tilray Brands, Inc. (NasdaqGS:TLRY) acquired 1000652011 Ontario Inc. from MediPharm Labs Corp. (TSX:LABS) for CAD 8.5 million.

MediPharm Labs Corp. Settles an Outstanding Claim for $9,000,000 with HEXO Corp

MediPharm Labs Corp. Launches New GMP Products to the Australian Medical Cannabis Market

Medipharm Labs Corp. Publishes Study Investigating Medical Cannabis Impacts on Anxiety and Depression Outcomes in Fibromyalgia Patients

New major risk - Financial position

Second quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.03 loss in 2Q 2022)

MediPharm Labs Corp. to Report Q2, 2023 Results on Aug 14, 2023

MediPharm Labs Corp. Provides Update on US FDA Status

First quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.03 loss in 1Q 2022)

MediPharm Labs Corp. to Report Q1, 2023 Results on May 15, 2023

High number of new and inexperienced directors

MediPharm Labs Corp. (TSX:LABS) entered into a definitive arrangement agreement to acquire VIVO Cannabis Inc. (TSX:VIVO) from directors and officers of VIVO and others for CAD 11.1 million.

Third quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.03 loss in 3Q 2021)

MediPharm Labs Corp. to Report Q3, 2022 Results on Nov 14, 2022

Onelife Botanicals Pty Ltd completed the acquisition of MediPharm Labs Australia Pty Ltd from MediPharm Labs Corp. (TSX:LABS).

Second quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.05 loss in 2Q 2021)

MediPharm Labs Corp. to Report Q2, 2022 Results on Aug 15, 2022

Onelife Botanicals Pty Ltd entered into an agreement to acquire MediPharm Labs Australia Pty Ltd from MediPharm Labs Corp. (TSX:LABS) for AUD 6.9 million.

Dr. Paul Tam Resigns from the Board of Directors of MediPharm Labs Corp

First quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.07 loss in 1Q 2021)

MediPharm Labs Corp. to Report Q1, 2022 Results on May 16, 2022

High number of new and inexperienced directors

MediPharm Labs Corp., Annual General Meeting, Jun 30, 2022

MediPharm Labs Corp. Announces Management Changes

Medipharm Labs Corp Launches CBG and Water-Soluble Products

Full year 2021 earnings released: CA$0.22 loss per share (vs CA$0.48 loss in FY 2020)

MediPharm Labs Corp. to Report Q4, 2021 Results on Mar 31, 2022

MediPharm Labs Corp. to Report Q4, 2021 Results on Mar 31, 2022

Medipharm Labs Enters United States Pharmaceutical Market with Submission of FDA DMF

CEO of Asia Pacific & Director recently sold €60k worth of stock

MediPharm Labs Expands CBN Portfolio with Two New Products

Third quarter 2021 earnings released: CA$0.03 loss per share (vs CA$0.11 loss in 3Q 2020)

Second quarter 2021 earnings released: CA$0.05 loss per share (vs CA$0.02 loss in 2Q 2020)

MediPharm Labs Corp. Receives Canadian GMP Pharmaceutical Drug Establishment Licence

Founder & Chairman of the Board recently sold €329k worth of stock

Independent Director recently bought €206k worth of stock

MediPharm Labs Launches High-CBD Wellness Oils in Quebec

First quarter 2021 earnings released: CA$0.07 loss per share (vs CA$0.13 loss in 1Q 2020)

Full year 2020 earnings released: CA$0.48 loss per share (vs CA$0.014 profit in FY 2019)

MediPharm Labs Expands Distribution Revenue Footprint in Canada, Enters Growing Quebec Market Through New Supply Agreement

Independent Director recently bought €132k worth of stock

Medipharm Labs Corp. Announces Plan to Launch New Over-The-Counter Products

MediPharm Labs Corp. has completed a Composite Units Offering in the amount of CAD 29 million.

Interim Chief Financial Officer has left the company

New 90-day high: €0.57

MediPharm Labs Corp. Appoints Greg Hunter as Chief Financial Officer, Effective February 8, 2021

MediPharm Labs Appoints Warren Everitt to Board of Directors

MediPharm Labs Corp. Enters a Supply Agreement with Nova Scotia Liquor Corporation

New 90-day low: €0.32

MediPharm Labs Corp. Announces Executive Changes

Revenue misses expectations

Third quarter 2020 earnings released: CA$0.11 loss per share

New 90-day low: €0.47